Device-Detected Atrial Tachyarrhythmias Predict Adverse Outcome in Real-World Patients With Implantable Biventricular Defibrillators
- 11 January 2011
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 57 (2), 167-172
- https://doi.org/10.1016/j.jacc.2010.08.624
Abstract
ObjectivesThe purpose of this analysis was to evaluate the correlation between atrial tachycardia (AT) or atrial fibrillation (AF) and clinical outcomes in heart failure (HF) patients implanted with a cardiac resynchronization therapy defibrillator (CRT-D).BackgroundIn HF patients, AT and AF have high prevalence and are associated with compromised hemodynamic function.MethodsForty-four Italian cardiological centers followed up 1,193 patients who received a CRT-D according to current guidelines for advanced HF, New York Heart Association functional class ≥II, left ventricular ejection fraction ≤35%, and QRS complex ≥120 ms. All patients were in sinus rhythm at implant.ResultsDuring a median follow-up period of 13 months, AT/AF >10 min occurred in 361 of 1,193 (30%) patients. The composite end point (deaths or HF hospitalizations) occurred in 174 of 1,193 (14.6%). Multivariate time-dependent Cox regression analyses showed that composite end point risk was higher among patients with device-detected AT/AF (hazard ratio [HR]: 2.16, p = 0.032), New York Heart Association functional class III or IV compared with II (HR: 2.09, p = 0.002), and absence of beta-blockers (HR: 1.36, p = 0.036). Furthermore, the composite end point risk was inversely associated with left ventricular ejection fraction (HR: 1.04, p = 0.045), increasing by a factor of 4% for each 1% decrease in left ventricular ejection fraction.ConclusionsIn HF patients with CRT-D, device-detected AT/AF is associated with a worse prognosis. Continuous device diagnostics monitoring and Web-based alerts may inform the physician of AT/AF occurrences and identify patients at risk of cardiac deterioration or patients with suboptimal rate or rhythm control. (Italian ClinicalService Project; NCT01007474Keywords
Funding Information
- Medtronic
- St. Jude
- Medtronic
- Medtronic
- Boston Scientific
- St. Jude
- Sorin SpA
This publication has 13 references indexed in Scilit:
- Clinical importance of new-onset atrial fibrillation after cardiac resynchronization therapyHeart Rhythm, 2008
- Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillationEuropean Heart Journal, 2008
- Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm AssociationEuropean Heart Journal, 2007
- ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive SummaryJournal of the American College of Cardiology, 2006
- Four-Year Efficacy of Cardiac Resynchronization Therapy on Exercise Tolerance and Disease ProgressionJournal of the American College of Cardiology, 2006
- Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart FailureCirculation, 2006
- Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillationHeart Rhythm, 2006
- The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart FailureNew England Journal of Medicine, 2005
- Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on MortalityCirculation, 2003
- Impact of Atrial Fibrillation on the Risk of DeathCirculation, 1998